Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Increased Platelet FcɣRIIa Identifies Patients at Greater Risk of Multiple Cardiovascular Events After Myocardial Infarction.

JACC. Advances·2026
Same author

Platelet FcɣRIIa Expression Refines Clinical Risk Assessment After Myocardial Infarction.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2026
Same author

Platelet FcɣRIIa: a novel biomarker of risk for thromboembolism and death in cancer.

Journal of thrombosis and thrombolysis·2026
Same author

Beyond PBMCs: Polymer-Based Cell Mimics for Robust TBNK Immunophenotyping Assay Validation.

Cytometry. Part A : the journal of the International Society for Analytical Cytology·2026
Same author

Platelet FcγRIIa Expression in Ischemic Stroke: A Marker of Increased Platelet Reactivity.

Stroke (Hoboken, N.J.)·2026
Same author

Prognostic implications over time of platelet FcɣRIIa expression in patients with myocardial infarction: a secondary analysis.

The Journal of invasive cardiology·2025

Related Experiment Video

Updated: Jun 14, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

822

Assessing prognosis by quantifying FcγRIIa on fixed platelets.

David J Schneider1, Heidi S Taatjes-Sommer1, Peter M DiBattiste2

  • 1Department of Medicine, Cardiovascular Research Institute, The University of Vermont, Burlington, VT, 05401, USA.

Bioanalysis
|September 4, 2024
PubMed
Summary

A modified test accurately quantifies FcγRIIa on fixed platelets, improving precision for identifying cardiovascular event risk. This enhanced platelet FcγRIIa quantification aids clinical assessment.

Keywords:
accuracybiomarkerplateletprecisionprognosis

More Related Videos

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

513
A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry
04:32

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry

Published on: June 5, 2019

7.6K

Related Experiment Videos

Last Updated: Jun 14, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

822
Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

513
A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry
04:32

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry

Published on: June 5, 2019

7.6K

Area of Science:

  • Immunology
  • Hematology
  • Biotechnology

Background:

  • FcγRIIa amplifies platelet activation, and elevated levels indicate higher cardiovascular event risk.
  • Accurate quantification of FcγRIIa on platelets is crucial for risk stratification.

Purpose of the Study:

  • To report the accuracy and precision of a modified test for quantifying FcγRIIa on fixed platelets (pFCG test).

Main Methods:

  • Developed a novel antibody clone (5G1) targeting formaldehyde-treated FcγRIIa.
  • Evaluated test accuracy and precision using biologic platelets and engineered synthetic cells.
  • Assessed intra-assay and interassay coefficients of variation (CV).

Main Results:

  • The modified pFCG test on fixed platelets detected ~300 molecules more FcγRIIa compared to non-fixed platelets.
  • Intra-assay CV was 2.1% ± 0.1% for biologic specimens.
  • Interassay CVs were 4.5% ± 1% (intraday) and 6.5% ± 0.4% (interday up to 5 days).
  • Synthetic cells showed accuracy, linearity (R²=0.984), and interassay CVs of 2% ± 0.6% (intraday) and 9.9% ± 2.1% (interday).

Conclusions:

  • Modification of the pFCG test for fixed platelets enables accurate FcγRIIa quantification.
  • The modified test demonstrates high precision, suitable for clinical applications.
  • Improved FcγRIIa measurement aids in identifying patients at risk for cardiovascular events.